Description
Parkinson et parkinsonismes
- Ageing-driven gastrointestinal variability in Parkinson's disease: implications for oral levodopa pharmacokinetics and formulation designon 20 juillet 2026
Eur J Pharm Biopharm. 2026 Jul 7:115179. doi: 10.1016/j.ejpb.2026.115179. Online ahead of print.ABSTRACTParkinson's disease is a distinctly age-associated neurodegenerative disorder in which oral […]
- Digital profiling of dysarthria in late- and early-onset Parkinson's diseaseon 20 juillet 2026
J Parkinsons Dis. 2026 Jul 15:1877718X261467587. doi: 10.1177/1877718X261467587. Online ahead of print.ABSTRACTBackgroundDigital speech analysis affords robust markers of Parkinson's disease (PD). […]
- Rationale and current status of fecal microbiota transplantations for Parkinson's diseaseon 20 juillet 2026
J Parkinsons Dis. 2026 Jun 24:1877718X261455608. doi: 10.1177/1877718X261455608. Online ahead of print.ABSTRACTTreating a neurological disorder through the gut may seem counterintuitive, yet multiple […]
- Mortality rate, main causes of death and factors associated with higher mortality hazard in late stage Parkinson's diseaseon 20 juillet 2026
J Parkinsons Dis. 2026 Jun 26:1877718X261463369. doi: 10.1177/1877718X261463369. Online ahead of print.ABSTRACTBackgroundA cohort of 107 patients in late stage Parkinson's disease (PD) was followed […]
- Helicobacter pylori infection, peptic ulcer, gastritis and risk of Parkinson's disease: A nationwide matched cohort studyon 20 juillet 2026
J Parkinsons Dis. 2026 Jul 15:1877718X261466875. doi: 10.1177/1877718X261466875. Online ahead of print.ABSTRACTBackgroundGastrointestinal symptoms are frequent in Parkinson's disease (PD) and may […]
- Mapping the Parkinson's pandemic: Unveiling and addressing the global burdenon 20 juillet 2026
J Parkinsons Dis. 2026 Jun 23:1877718X261459875. doi: 10.1177/1877718X261459875. Online ahead of print.ABSTRACTWorldwide, the incidence, prevalence, disability, and mortality associated with […]
- Basal ganglia neurophysiological markers of non-motor symptoms in Parkinson's disease: A systematic reviewon 20 juillet 2026
J Parkinsons Dis. 2026 Jun 23:1877718X261459224. doi: 10.1177/1877718X261459224. Online ahead of print.ABSTRACTBackgroundDeep brain stimulation (DBS) for Parkinson's disease (PD) primarily improves […]
- Association Between Plasma Phosphorylated Tau-217 and Cognition in Parkinson's Diseaseon 20 juillet 2026
Mov Disord. 2026 Jul 19. doi: 10.1002/mds.70400. Online ahead of print.ABSTRACTBACKGROUND: Alzheimer's disease (AD) co-pathology contributes to dementia in PD, but its role in earlier cognitive […]
- Exploring MAPT-containing H1 and H2 haplotypes in Parkinson's disease across diverse populationson 20 juillet 2026
NPJ Parkinsons Dis. 2026 Jun 24. doi: 10.1038/s41531-026-01394-9. Online ahead of print.ABSTRACTVariation at the 17q21.31 locus, which contains the gene encoding microtubule-associated protein tau […]
- Measurement fidelity, not model complexity, governs individual cognitive trajectory prediction in Parkinson's diseaseon 22 juin 2026
npj Digital Medicine, Published online: 06 June 2026; doi:10.1038/s41746-026-02681-8Measurement fidelity, not model complexity, governs individual cognitive trajectory prediction in Parkinson's […]
Traitements pharmacologiques
Médicaments
- Functional connectivity in neurologically healthy aging and Parkinson's Disease: Investigating the role of age and medicationon 20 juillet 2026
Eur J Neurosci. 2026 Jul;64(1):e70617. doi: 10.1111/ejn.70617.ABSTRACTBoth aging and Parkinson's disease (PD) are associated with cognitive decline. Although electroencephalography (EEG) has been […]
- Cardiovascular autonomic dysfunction in Parkinson's disease: associations with disease severity and the modulatory role of dopaminergic therapyon 20 juillet 2026
Arq Neuropsiquiatr. 2026 Jun;84(6):1-10. doi: 10.1055/s-0046-1825525. Epub 2026 Jul 14.ABSTRACTBACKGROUND: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by both motor […]
- Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Studyon 20 juillet 2026
Clin Neuropharmacol. 2026 Jul-Aug 01;49(4):155-160. doi: 10.1097/WNF.0000000000000686. Epub 2026 Apr 17.ABSTRACTOBJECTIVES: A ropinirole patch provides continuous dopaminergic stimulation, permitting […]
- Neuroinflammation in neurodegenerative diseases: pathogenic pathways and emerging pharmacotherapeutic targets in Alzheimer's and Parkinson's diseaseon 20 juillet 2026
Inflammopharmacology. 2026 Jul 7. doi: 10.1007/s10787-026-02325-z. Online ahead of print.ABSTRACTNeuroinflammation is now widely recognized as a key contributor to the initiation and progression of […]
- The road towards faster development of novel pharmacotherapies for persons with Parkinson's diseaseon 20 juillet 2026
J Parkinsons Dis. 2026 Jul;16(2_suppl):3-5. doi: 10.1177/1877718X261463419. Epub 2026 Jul 3.NO ABSTRACTPMID:42399098 | DOI:10.1177/1877718X261463419
- Is Urolithin A(UA) a Pharmacologically Credible Neuro-Nutraceutical? A Critical Review of Mechanisms, Brain Exposure, and Evidence Gaps in Alzheimer's and Parkinson's Diseaseon 20 juillet 2026
Neurochem Int. 2026 Jul 17:106224. doi: 10.1016/j.neuint.2026.106224. Online ahead of print.ABSTRACTUrolithin A(UA) is a gut microbiota-derived metabolite of dietary ellagitannins and ellagic acid, […]
- Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?on 20 juillet 2026
J Parkinsons Dis. 2026 Jul 10:1877718X261431104. doi: 10.1177/1877718X261431104. Online ahead of print.ABSTRACTDopaminergic drugs represent the cornerstone in the symptomatic management of […]
Études cliniques phase 3 et phase 4
- The conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheseson 20 juillet 2026
Ther Adv Neurol Disord. 2026 Jul 14;19:17562864261465665. doi: 10.1177/17562864261465665. eCollection 2026.ABSTRACTParkinson's disease (PD) remains the second most common neurodegenerative disorder […]
- Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trialon 20 juillet 2026
Lancet Neurol. 2026 Aug;25(8):721-730. doi: 10.1016/S1474-4422(26)00215-2.ABSTRACTBACKGROUND: Current dopaminergic therapies for Parkinson's disease carry significant limitations: levodopa can cause […]
- Sit-to-stand strategies and anticipatory momentum transfer adjustments in individuals with Parkinson's disease using markerless motion capture: a cross-sectional studyon 20 juillet 2026
Sci Rep. 2026 Jul 13. doi: 10.1038/s41598-026-62250-7. Online ahead of print.ABSTRACTParkinson's disease (PD) impairs sit-to-stand performance due to bradykinesia and postural instability; however, […]
- Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialon 20 juillet 2026
Lancet. 2026 Jun 22:S0140-6736(26)01241-9. doi: 10.1016/S0140-6736(26)01241-9. Online ahead of print.NO ABSTRACTPMID:42330995 | DOI:10.1016/S0140-6736(26)01241-9
- Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12on 20 juillet 2026
J Med Chem. 2026 Jun 18. doi: 10.1021/acs.jmedchem.6c00763. Online ahead of print.ABSTRACTGPR3, GPR6, and GPR12 form a subfamily of Class A orphan G protein-coupled receptors (oGPCRs), for which […]
Traitements non pharmacologiques
Chirurgie
- Comparative Efficacy of Non-invasive Brain Stimulation for Pain, Anxiety, and Depression: A Systematic Review and Network Meta-analysison 20 juillet 2026
Pain Ther. 2026 Jul 11. doi: 10.1007/s40122-026-00860-9. Online ahead of print.ABSTRACTINTRODUCTION: Although non-invasive brain stimulation (NIBS) has been used to manage chronic musculoskeletal […]
- Deep brain stimulation for the treatment of patients with dystonia: advances towards network-based personalised careon 20 juillet 2026
Lancet Neurol. 2026 Aug;25(8):781-788. doi: 10.1016/S1474-4422(26)00192-4.ABSTRACTDystonia is a complex movement disorder that can cause functional disability and reduce quality of life. Deep brain […]
- Repetitive transcranial magnetic stimulation for freezing of gait in Parkinson's disease: a systematic review and meta-analysison 20 juillet 2026
Clin Park Relat Disord. 2026 Jun 15;15:100465. doi: 10.1016/j.prdoa.2026.100465. eCollection 2026.ABSTRACTBACKGROUND: Freezing of gait is among the most disabling motor complications of Parkinson's […]
- Long-lasting concordance between imaging-guided and clinical-based STN-DBS programming enhances motor and axial outcomes in Parkinson's disease: A 3-year single-center studyon 20 juillet 2026
J Parkinsons Dis. 2026 Jul 7:1877718X261428281. doi: 10.1177/1877718X261428281. Online ahead of print.ABSTRACTIntroductionSubthalamic deep brain stimulation (STN-DBS) improves Parkinson's disease […]
- Age, emotional burden and deep brain stimulation electrode location shape Parkinson’s disease quality of lifeon 22 juin 2026
npj Digital Medicine, Published online: 05 June 2026; doi:10.1038/s41746-026-02828-7Age, emotional burden and deep brain stimulation electrode location shape Parkinson’s disease quality of life
Approches multidisciplinaires
- Serious games and virtual reality in Parkinson's disease rehabilitation: A systematic review of randomized controlled trialson 20 juillet 2026
Parkinsonism Relat Disord. 2026 Jun 30;149:108408. doi: 10.1016/j.parkreldis.2026.108408. Online ahead of print.ABSTRACTBACKGROUND: Serious games (SG) and virtual reality (VR) are emerging […]
- Efficacy of a Slow Waltz-Based Program on Gait and Balance Problems in Parkinson's Disease: A Pilot Studyon 20 juillet 2026
J Dance Med Sci. 2026 Jul 3:1089313X261461437. doi: 10.1177/1089313X261461437. Online ahead of print.ABSTRACTINTRODUCTION: Parkinson's disease (PD) is a progressive neurodegenerative disorder […]
- Comparative Effects of Land-Based and Aquatic Physiotherapy on Functional and Neuromuscular Outcomes in the Rigid-Akinetic Subtype of Parkinson's Disease: A Randomized Clinical Trialon 20 juillet 2026
Physiother Res Int. 2026 Jul;31(3):e70269. doi: 10.1002/pri.70269.ABSTRACTBACKGROUND: Parkinson's disease (PD) leads to motor and neuromuscular impairments, with the rigid-akinetic (RA) subtype […]
- Does Resistance Training Improve the Quality of Life of People With Parkinson's Disease? Evidence and Recommendations for Clinical Application Through a Systematic Review and Meta-Analysis of Randomized Clinical Trialson 20 juillet 2026
Physiother Res Int. 2026 Jul;31(3):e70266. doi: 10.1002/pri.70266.ABSTRACTBACKGROUND: Parkinson's disease is a neurological condition with motor and non-motor symptoms that negatively affect […]
Thérapies alternatives
- Exercise, exerkines, and muscle-brain crosstalk in Parkinson's diseaseon 29 juillet 2026
Neuroprotection. 2026 Feb 25;4(2):99-110. doi: 10.1002/nep3.70032. eCollection 2026 Jun.ABSTRACTParkinson's disease (PD) is a progressive neurodegenerative disorder with motor and non-motor symptoms, […]
- Creative thinking in Parkinson's disease: A systematic review and meta-analysison 20 juillet 2026
Neurol Sci. 2026 Jul 16;47(8):632. doi: 10.1007/s10072-026-09234-7.ABSTRACTINTRODUCTION: Creativity in Parkinson's disease (PD) has aroused research interest due to its neurological underpinnings, […]
- Structural and functional brain changes following diverse exercise interventions in Parkinson's disease: an MRI-based narrative reviewon 20 juillet 2026
Phys Act Nutr. 2026 Jun;30(2):14-22. doi: 10.20463/pan.2026.0015. Epub 2026 Jun 30.ABSTRACTPURPOSE: This narrative review synthesizes magnetic resonance imaging (MRI) evidence from exercise […]
- Non-Pharmacological Constipation Management in People With Neurodegenerative Disease: A Scoping Reviewon 20 juillet 2026
West J Nurs Res. 2026 Jul 16:1939459261451721. doi: 10.1177/01939459261451721. Online ahead of print.ABSTRACTBACKGROUND: Constipation is a common symptom among people with neurodegenerative diseases […]
Qualité de vie des patients
- Parkinson's disease and awareness of the passage of time: Perceived health, emotion, and self-transcendenceon 20 juillet 2026
PLoS One. 2026 Jul 17;21(7):e0352176. doi: 10.1371/journal.pone.0352176. eCollection 2026.ABSTRACTThis study examined passage-of-time judgments in patients with Parkinson's disease, compared to […]
- Perceived knowledge, attitudes and practices of Parkinson's disease patients and their families regarding exercise rehabilitation: a cross-sectional survey across 27 provinces in Chinaon 20 juillet 2026
Sci Rep. 2026 Jul 10. doi: 10.1038/s41598-026-61121-5. Online ahead of print.ABSTRACTParkinson's disease (PD) significantly impacts motor function and psychosocial wellbeing, with exercise […]
- Effects of Technology-Based Perturbation Training During Walking on Physical Function in Stroke, Multiple Sclerosis, and Parkinson's Disease: A Scoping Reviewon 20 juillet 2026
NeuroRehabilitation. 2026 Jul 2:10538135261462948. doi: 10.1177/10538135261462948. Online ahead of print.ABSTRACTBackgroundStroke, multiple sclerosis (MS), and Parkinson's disease (PD) cause balance […]
- 'Partnering With Poise': A Preliminary Study of an Alexander Technique-Based Group Course for Informal Care Partnerson 20 juillet 2026
Int J Geriatr Psychiatry. 2026 Jul;41(7):e70233. doi: 10.1002/gps.70233.ABSTRACTOBJECTIVE: Informal care partners often experience role-engulfment and decreased quality of life. Alexander technique […]
- Supporting Parkinson's Disease Caregivers and Training Future Psychiatric-Mental Health Nurse Practitioners: Feasibility and Acceptability of a Student-Led Virtual Support Groupon 20 juillet 2026
J Psychosoc Nurs Ment Health Serv. 2026 Jul 17:1-7. doi: 10.3928/02793695-20260710-04. Online ahead of print.ABSTRACTPURPOSE: Parkinson's disease (PD) caregivers face significant emotional, physical, […]
- Perceived consequences and catastrophising help explain health-related quality of life in Parkinson's disease. A cross-sectional studyon 20 juillet 2026
Parkinsonism Relat Disord. 2026 Jul 10;150:108421. doi: 10.1016/j.parkreldis.2026.108421. Online ahead of print.ABSTRACTINTRODUCTION: Motor complications are major determinants of disability in […]
- Unraveling the mediating role of anxiety and depression: Cultivating mindfulness to improve quality of life in Parkinson's disease patientson 20 juillet 2026
Geriatr Nurs. 2026 Jun 27;72:104172. doi: 10.1016/j.gerinurse.2026.104172. Online ahead of print.ABSTRACTOBJECTIVE: To explore the associations between mindfulness, psychological distress, and […]
Technologies de soutien
- A qualitative exploration of the low-resource tele-assisted home exercise program for balance and functional mobility in Parkinson's disease (TELEPORT-PD)on 20 juillet 2026
PLOS Digit Health. 2026 Jun 30;5(6):e0001536. doi: 10.1371/journal.pdig.0001536. eCollection 2026 Jun.ABSTRACTThis study explores the perspectives of people with Parkinson's disease (PD) on […]
- Does the Type of Online Group-based Exercise Influence the Feasibility of Telerehabilitation in People with Parkinson's Disease? A Randomized Controlled Trialon 20 juillet 2026
Int J Telerehabil. 2026 Jun 1;18(1):6748. doi: 10.63144/ijt.2026.6748. eCollection 2026.ABSTRACTBACKGROUND: Ensuring equitable access to effective interventions for people with Parkinson's disease […]
- Comparison of the Effects of Telerehabilitation-Based Motor and Cognitive Dual-Task Exercises in Patients With Parkinson's Disease-A Randomized Controlled Studyon 20 juillet 2026
J Aging Phys Act. 2026 Jul 16:1-11. doi: 10.1123/japa.2026-0190. Online ahead of print.ABSTRACTBACKGROUND/OBJECTIVES: The co-occurrence of motor and cognitive impairments in Parkinson's disease […]
- Parkinson's disease focused multimodal wearable vision based gait monitoring system with real time feedback to support mobility and caregiver well-beingon 20 juillet 2026
Discov Ment Health. 2026 Jul 9. doi: 10.1007/s44192-026-00539-9. Online ahead of print.ABSTRACTA chronic and progressive neurological disorder, Parkinson's disease (PD) has a significant influence on […]
- Real-world gait study of Parkinson's disease using wearable sensors: a systematic reviewon 20 juillet 2026
J Neuroeng Rehabil. 2026 Jun 17. doi: 10.1186/s12984-026-01957-0. Online ahead of print.ABSTRACTBACKGROUND: New technologies, such as wearable sensors, allow the quantitative assessment of gait […]
- Bridging the global Parkinson's divide: Technology as a structural solution for equitable and brain health-integrated careon 20 juillet 2026
J Parkinsons Dis. 2026 Jul 7:1877718X261466810. doi: 10.1177/1877718X261466810. Online ahead of print.ABSTRACTParkinson's disease (PD) is the fastest-growing neurodegenerative disorder worldwide, […]
Associations et ordres professionnels
Québec
- 🚴♀️ Bonne nouvelle : le Défi Vélo se vit aussi à distance !on 20 juillet 2026
🚴♀️ Bonne nouvelle : le Défi Vélo se vit aussi à distance ! Participez où que vous soyez, à votre rythme 🙌 Sur votre piste cyclable préférée, en BIXI ou même sur un vélo […]
- 📣Depuis le 25 juin 2026, la RAMQ couvre désormais le traitement par foslévodopa/foscarbidopa (Vyalev) grâce à l’ajout de deux no...on 20 juillet 2026
📣Depuis le 25 juin 2026, la RAMQ couvre désormais le traitement par foslévodopa/foscarbidopa (Vyalev) grâce à l’ajout de deux nouveaux codes de médicament d’exception. Cette mesure […]
- 📣 Recherche de participants - Étude sur le sommeil et l'exercice dans la maladie de Parkinson McGill Universityon 20 juillet 2026
📣 Recherche de participants - Étude sur le sommeil et l'exercice dans la maladie de Parkinson McGill University Le Memory and Motor Laboratory (MEMORY LAB) et le Human Brain Control of […]
- 🎉 130 000 $ déjà amassés !on 20 juillet 2026
🎉 130 000 $ déjà amassés ! 🎉 🚴 La 16e édition vise à atteindre 400 000 $ pour financer la recherche et soutenir les services offerts aux personnes touchées par la maladie de […]
- 🔎 Appel à la participation – Étude sur la kinésiophobie et la maladie de Parkinsonon 20 juillet 2026
🔎 Appel à la participation – Étude sur la kinésiophobie et la maladie de Parkinson Certaines personnes peuvent ressentir une appréhension ou une peur lorsqu'il s'agit de bouger ou de […]
- 🌴 Cette année, le Défi Vélo Parkinson Québec vous réserve une surprise exceptionnelle !on 20 juillet 2026
🌴 Cette année, le Défi Vélo Parkinson Québec vous réserve une surprise exceptionnelle ! En participant au Défi, vous courez la chance de remporter un séjour de 7 nuits pour 2 personnes […]
- 💙 Cet été, découvrez les témoignages inspirants de notre communautéon 20 juillet 2026
💙 Cet été, découvrez les témoignages inspirants de notre communauté. 🎥 Aujourd’hui, faites la rencontre de Serge Boily, qui a choisi de s’impliquer activement dans la recherche […]
- 📢 Recherche de participantson 20 juillet 2026
📢 Recherche de participants L'équipe étudiante BiosensUM de l'Université de Montréal recherche des participants pour contribuer au développement d'un appareil de détection portable […]
- 📣 Appel à participation à des essais cliniques au CHUMon 20 juillet 2026
📣 Appel à participation à des essais cliniques au CHUM 🔬 ÉTUDE PARAISO Étude clinique de phase III portant sur le prasinézumab, un traitement ciblant l’alpha-synucléine, administré […]
Canada
- Une fois de plus : David Walker retourne au T100 Triathlonon 20 juillet 2026
En août prochain, David Walker participera au T100 Triathlon à Vancouver — une fois de plus. Mais pour David, qui vit avec le Parkinson, il ne s’agit pas simplement d’une autre course : […]
- Le pouvoir du mouvement : l’exercice et le Parkinsonon 20 juillet 2026
L’exercice est l’un des moyens les plus efficaces de soutenir la santé et le bien-être des personnes atteintes de le Parkinson, car il complète les soins professionnels pour aider à maintenir […]
- Every movement countson 20 juillet 2026
Build movement into your routine View this email in your browser What moves you? Maybe it’s a walk around the block, gardening, […]
- You're invited - It takes a team: finding the right people for your careon 20 juillet 2026
Join our July webinar View this email in your browser Living with Parkinson’s can be challenging, but you don’t have to face it […]
États-Unis
- Study ties gut bacteria to dopamine, Parkinson’s motor controlon 20 juillet 2026
Gut bacteria that produce vitamin B6 may help nerve cells in the brain produce dopamine, a chemical involved in motor control that is missing in Parkinson’s disease, according to an animal study. […]
- New data back safety of treatment to replace lost Parkinson’s nerve cellson 20 juillet 2026
An investigational stem cell-based therapy that would replace the nerve cells, or neurons, lost due to Parkinson’s disease was found to be generally safe and feasible for use after one year of […]
- US biotech secures $150M to develop potential treatments for Parkinson’son 20 juillet 2026
Mighty Therapeutics, a Massachusetts-based biotech company, announced that it has raised $150 million to support the clinical development of its treatment candidates for Parkinson’s disease and […]
- Muscle mass alone does not explain fitness drops in Parkinson’son 20 juillet 2026
Older people with Parkinson’s disease who engage in regular exercise tend to perform worse on measures of physical fitness than similarly aged adults without the disease, but these differences are […]
- Review spotlights gut bacteria as possible Parkinson’s treatment targeton 20 juillet 2026
A growing body of research suggests that the gut microbiome — the community of bacteria and other microscopic organisms that live in the human digestive tract — may play key roles in the […]
- ‘Thaw-and-inject’ cells given to new groups in Parkinson’s trialon 20 juillet 2026
Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these […]
- Approval of Parkinson’s therapy urged in Europe under brand name Hopledoon 20 juillet 2026
A European Medicines Agency (EMA) committee is recommending approval of Hopledo (IPX203) — an oral extended-release formulation of levodopa and carbidopa sold in the U.S. under the brand name […]
- Adaptive brain stimulation responds in real time to reduce Parkinson’s fallson 20 juillet 2026
A new personalized, adaptive deep brain stimulation (aDBS) system developed by researchers at the University of California, San Francisco (UCSF) helped improve gait and reduce falls in a small […]
- New Study Suggests “Exercise Hormone” Irisin May Slow PD Progressionon 20 juillet 2026
New Study Suggests “Exercise Hormone” Irisin May Slow PD Progression Exercise, Irisin, and Brain Health Exercise has long been associated with better brain health, and now research […]
- Parkinson’s Before Diagnosis: Early Warning Signson 20 juillet 2026
Smart Patients Blog Series 1 of 5: Dr. Gilbert Discusses Early Symptoms of Parkinson’s Some early symptoms of Parkinson’s disease (PD) can begin many years before the classic motor […]
International
- Parkinson’s passport helps thousands enjoy smoother travelon 20 juillet 2026
‘Parkinson’s passport’ makes travelling easier The post Parkinson’s passport helps thousands enjoy smoother travel appeared first on Parkinson's Europe.
- Airports have “more to learn” about accessibility for travellers with hidden disabilities like Parkinson’s, airport organisation...on 20 juillet 2026
Airports have “more to learn” about accessibility for travellers with hidden disabilities like Parkinson’s, an organisation representing European airports has admitted. Federico Bonaudi, […]
- Travel advice for people with Parkinson’s – the Parkinson’s community share their best tipson 20 juillet 2026
Sunsoaked beaches or famous landmarks? Rest and relaxation or intrepid adventures? There is no doubt travel can open up the door to new experiences and allow us to escape the everyday grind. But […]
- Parkinson : comprendre comment les protéines toxiques s’accumulent dans les neuroneson 16 juin 2026
https://theconversation.com/parkinson-comprendre-comment-les-proteines-toxiques-saccumulent-dans-les-neurones-251501 À l’heure actuelle, il n’existe aucun traitement curatif contre la maladie […]
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
|
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |


